Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

27 mars 2026 02h05 HE | Source: Excellergy, Inc.

Excellergy to be acquired by Novartis for up to USD 2 billion to advance potentially first-in-class trifunctional effector cell response inhibitors

Excellergy to be acquired by Novartis for up to USD 2 billion to advance potentially first-in-class trifunctional effector cell response inhibitors
27 févr. 2026 15h45 HE | Source: Excellergy, Inc.

Excellergy Presents New Data at 2026 AAAAI Annual Meeting Demonstrating Rapid and Sustained Allergic Effector Cell Control and Announces First Subjects Dosed in Phase 1 DISARM Trial

Excellergy Presents New Data at 2026 AAAAI Annual Meeting Demonstrating Rapid and Sustained Allergic Effector Cell Control
23 nov. 2022 05h57 HE | Source: Fortune Business Insights

With 5.4% CAGR, Allergic Conjunctivitis Market Size worth USD 3.60 Billion in 2028

Pune, India, Nov. 23, 2022 (GLOBE NEWSWIRE) -- The global allergic conjunctivitis market size is projected to reach USD 3.60 billion by 2028, exhibiting a CAGR of 5.4% during the forecast period....